Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase

被引:14
作者
Bhojwani, Heena R. [1 ]
Joshi, Urmila J. [1 ]
机构
[1] Univ Mumbai, Prin KM Kundnani Coll Pharm, Dept Pharmaceut Chem, Mumbai, Maharashtra, India
关键词
DFG-motif; docking; virtual screening; pharmacophore; quantitative structure-activity relationship; type I inhibitor; VEGFR-2; TYROSINE KINASES; PROTEIN-KINASES; DRUG DISCOVERY; DESIGN; POTENT; IDENTIFICATION; ANGIOGENESIS; PERMEABILITY; CONFORMATION; TARGETS;
D O I
10.2174/1386207319666161214112536
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Kinase domain of VEGFR-2 displays conformational flexibility which leads to existence of two kinds of inhibitors viz. type I and type II inhibitors. They exhibit different binding modes and this necessitates the development of separate pharmacophore models for them. Methods: The virtual screening study for discovery of type I inhibitors of VEGFR-2 kinase was done by using combined pharmacophore (generated using PHASE and validated by 3D-QSAR) and docking (Glide) based approach. Validated pharmacophore was used as preliminary filter followed by docking. ADME properties were predicted for retrieved hits using QikProp. Results: ADHRR.94 with statistical parameters r(test)(2)0.94, r(training)(2)0.99, SD 0.0766, r(2)0.9861, F 283.3, RMSE 0.2605, q(2)0.8115 and Pearson's R 0.9723 was identified as the best pharmacophore hypothesis for type I inhibitors of VEGFR-2 kinase. Virtual screening study was done for Asinex Elite Libraries comprising of 104400 molecules using ADHRR. 94, HTVS docking and XP docking that resulted in twelve hits. Asinex ligand 5686 with docking score of -10.48kcal/mol was top-ranking hit. It made two hydrogen bonding interactions with Cys 919, one as an acceptor and other as a donor, which are characteristic of type I inhibitors. Additional interactions observed were pi-cation with Lys 868 and pi-pi stacking with Phe 1047. Twelve hits had acceptable values for ADME properties. Conclusion: Twelve hits with best obtained docking scores ranging from -10.48 to - 7.23 kcal/mol and mimicking characteristic type I inhibitor interactions were identified which could be probable inhibitors of VEGFR-2.
引用
收藏
页码:186 / 207
页数:22
相关论文
共 45 条
  • [31] Design, synthesis, and evaluation of orally active Benzimidazoles and Benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors
    Potashman, Michele H.
    Bready, James
    Coxon, Angela
    DeMelfi, Thomas M., Jr.
    DiPietro, Lucian
    Doerr, Nicholas
    Elbaum, Daniel
    Estrada, Juan
    Gallan, Paul
    Germain, Julie
    Gu, Yan
    Harmange, Jean-Christophe
    Kaufman, Stephen A.
    Kendall, Rick
    Kim, Joseph L.
    Kumar, Gondi N.
    Long, Alexander M.
    Neervannan, Seshadri
    Patel, Vinod F.
    Polverino, Anthony
    Rose, Paul
    van der Plas, Simon
    Whittington, Douglas
    Zanon, Roger
    Zhao, Huilin
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (18) : 4351 - 4373
  • [32] Rajagopalan M., 2012, J ENZYM INHIB MED CH, V28, P1
  • [33] Rajappan R., 2015, PHARM CHEM, V7, P155
  • [34] In silico prediction of membrane permeability from calculated molecular parameters
    Refsgaard, HHF
    Jensen, BF
    Brockhoff, PB
    Padkjær, SB
    Guldbrandt, M
    Christensen, MS
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (03) : 805 - 811
  • [35] VEGF receptor protein-tyrosine kinases: Structure and regulation
    Roskoski, Robert, Jr.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 375 (03) : 287 - 291
  • [36] Vascular endothelial growth factor (VEGF) signaling in tumor progression
    Roskoski, Robert, Jr.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 62 (03) : 179 - 213
  • [37] 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors
    Tripathy, Rabindranath
    Ghose, Arup
    Singh, Jasbir
    Bacon, Edward R.
    Angeles, Thelma S.
    Yang, Shi X.
    Albom, Mark S.
    Aimone, Lisa D.
    Herman, Joseph L.
    Mallamo, John P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (06) : 1793 - 1798
  • [38] Ugale V.G., 2013, ARAB J CHEM
  • [39] Molecular properties that influence the oral bioavailability of drug candidates
    Veber, DF
    Johnson, SR
    Cheng, HY
    Smith, BR
    Ward, KW
    Kopple, KD
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) : 2615 - 2623
  • [40] Veerasamy R., 2011, INT J DRUG DES DIS, V2, P511, DOI DOI 10.1016/J.FEBSLET.2005.06.031